Cargando…
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9i) lower LDL-C by up to 60% and increase plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels by 10-fold. OBJECTIVES: The authors studied the reasons behind the robust increase in plasma PCSK...
Autores principales: | Oleaga, Carlota, Shapiro, Michael D., Hay, Joshua, Mueller, Paul A., Miles, Joshua, Huang, Cecilia, Friz, Emily, Tavori, Hagai, Toth, Peter P., Wójcik, Cezary, Warden, Bruce A., Purnell, Jonathan Q., Duell, P. Barton, Pamir, Nathalie, Fazio, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486917/ https://www.ncbi.nlm.nih.gov/pubmed/34593126 http://dx.doi.org/10.1016/j.jacc.2021.07.056 |
Ejemplares similares
-
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
por: Oleaga, Carlota, et al.
Publicado: (2020) -
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
por: Warden, Bruce A., et al.
Publicado: (2020) -
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
por: Warden, Bruce A., et al.
Publicado: (2020) -
New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015) -
Role of PAI-1 in hepatic steatosis and dyslipidemia
por: Levine, Joshua A., et al.
Publicado: (2021)